CA2378661A1 - Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines - Google Patents

Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines Download PDF

Info

Publication number
CA2378661A1
CA2378661A1 CA002378661A CA2378661A CA2378661A1 CA 2378661 A1 CA2378661 A1 CA 2378661A1 CA 002378661 A CA002378661 A CA 002378661A CA 2378661 A CA2378661 A CA 2378661A CA 2378661 A1 CA2378661 A1 CA 2378661A1
Authority
CA
Canada
Prior art keywords
piv
genome
chimeric
antigenome
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378661A
Other languages
English (en)
French (fr)
Inventor
Alexander C. Schmidt
Mario H. Skiadopoulos
Peter L. Collins
Brian R. Murphy
Jane E. Bailly
Anna P. Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378661A1 publication Critical patent/CA2378661A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA002378661A 1999-07-09 2000-06-15 Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines Abandoned CA2378661A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14313499P 1999-07-09 1999-07-09
US60/143,134 1999-07-09
PCT/US2000/017066 WO2001004320A1 (en) 1999-07-09 2000-06-16 Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Publications (1)

Publication Number Publication Date
CA2378661A1 true CA2378661A1 (en) 2001-01-18

Family

ID=22502741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378661A Abandoned CA2378661A1 (en) 1999-07-09 2000-06-15 Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Country Status (12)

Country Link
EP (3) EP1194564B1 (enExample)
JP (1) JP4813711B2 (enExample)
KR (1) KR100940776B1 (enExample)
CN (2) CN101392239A (enExample)
AT (1) ATE408693T1 (enExample)
BR (1) BR0013190A (enExample)
CA (1) CA2378661A1 (enExample)
DE (1) DE60040289D1 (enExample)
ES (1) ES2312347T3 (enExample)
IL (2) IL147167A0 (enExample)
MX (1) MXPA01013302A (enExample)
WO (1) WO2001004320A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US8722341B2 (en) 2001-01-19 2014-05-13 Vironovative B.V. Metapneumovirus strains and their use in vaccine formulations and sequences
US8841433B2 (en) 2002-02-21 2014-09-23 Vironovative Bv Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
EP1179054A2 (en) * 1999-12-10 2002-02-13 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2002002605A2 (en) * 2000-07-05 2002-01-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
ATE509097T1 (de) 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (ja) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
CN107818197B (zh) * 2017-09-15 2021-05-25 南京航空航天大学 一种基于piv技术的超声速翼型的测力方法和装置
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN113322241B (zh) * 2021-05-14 2023-06-13 金宇保灵生物药品有限公司 一种牛副流感病毒3型病毒株bpiv3-nm及其应用
CN116676275B (zh) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A基因型嵌合腮腺炎病毒株和制备方法及用途
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation
CN118909958B (zh) * 2024-07-25 2025-02-07 中国兽医药品监察所 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6165774A (en) * 1995-09-22 2000-12-26 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DE69842165D1 (de) * 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9803252B2 (en) 2001-01-19 2017-10-31 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US10167524B2 (en) 2001-01-19 2019-01-01 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US11162148B2 (en) 2001-01-19 2021-11-02 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
US9334543B2 (en) 2001-01-19 2016-05-10 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US9376726B2 (en) 2001-01-19 2016-06-28 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US8722341B2 (en) 2001-01-19 2014-05-13 Vironovative B.V. Metapneumovirus strains and their use in vaccine formulations and sequences
US10519517B2 (en) 2001-01-19 2019-12-31 Vironovative Bv Virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US9593386B2 (en) 2001-01-19 2017-03-14 Erasmus Universiteit Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US9834824B2 (en) 2002-02-21 2017-12-05 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9944997B2 (en) 2002-02-21 2018-04-17 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US10287640B2 (en) 2002-02-21 2019-05-14 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9567653B2 (en) 2002-02-21 2017-02-14 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US8841433B2 (en) 2002-02-21 2014-09-23 Vironovative Bv Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US11220718B2 (en) 2002-02-21 2022-01-11 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Also Published As

Publication number Publication date
IL147167A (en) 2010-06-16
WO2001004320A1 (en) 2001-01-18
KR100940776B1 (ko) 2010-02-11
EP2019140A2 (en) 2009-01-28
EP1194564A1 (en) 2002-04-10
EP2019141A2 (en) 2009-01-28
CN100402651C (zh) 2008-07-16
JP2003504064A (ja) 2003-02-04
JP4813711B2 (ja) 2011-11-09
IL147167A0 (en) 2002-08-14
CN1369011A (zh) 2002-09-11
KR20020022768A (ko) 2002-03-27
DE60040289D1 (de) 2008-10-30
EP2019140A3 (en) 2009-02-04
ATE408693T1 (de) 2008-10-15
EP1194564B1 (en) 2008-09-17
BR0013190A (pt) 2002-07-16
EP2019141A3 (en) 2009-02-04
CN101392239A (zh) 2009-03-25
MXPA01013302A (es) 2004-03-10
ES2312347T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
JP4237268B2 (ja) クローン化されたヌクレオチド配列からの弱毒化パラインフルエンザウィルスワクチンの製造
AU783993C (en) Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) Attenuated parainfluenza virus (PIV) vaccines
EP1194564B1 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
AU2009202359A1 (en) Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
EP1572947B1 (en) RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
US7622123B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
WO2002002605A2 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
AU783189B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130607